Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI response’s substantive label-related claims (boxed warning and associated warnings regarding opioid co-use, abuse/misuse/addiction, and dependence/withdrawal with tapering) are explicitly supported by the supplied Ativan (lorazepam) prescribing information excerpts. Non-label administrative/logistics claims about manufacturers and databases are not evaluated against labeling because they are not prescribing-information content.
Category Scores
Accurate Statements
Ativan/lorazepam has boxed-warning risks when used concomitantly with opioids, including profound sedation, respiratory depression, coma, and death.
BOXED WARNING: Risks from Concomitant Use with Opioids; WARNINGS (5): Risks from Concomitant Use with Opioids
Ativan/lorazepam can lead to abuse, misuse, and addiction.
BOXED WARNING; WARNINGS (5): Abuse, Misuse, and Addiction; DRUG ABUSE AND DEPENDENCE
Ativan/lorazepam can cause physical dependence with withdrawal reactions if discontinued abruptly or rapidly reduced, and withdrawal can be life-threatening.
BOXED WARNING: Dependence and Withdrawal Reactions; WARNINGS (5): Dependence and Withdrawal Reactions; DRUG ABUSE AND DEPENDENCE
Withdrawal risk should be reduced by using a gradual taper rather than abrupt discontinuation.
BOXED WARNING; WARNINGS (5): Dependence and Withdrawal Reactions; DOSAGE AND ADMINISTRATION (2): Discontinuation/Taper
Unsupported Statements
Ativan listings can be looked up by strength and dosage form in DrugPatentWatch.com’s database.
No prescribing-information support was provided for this claim; it is not content from the supplied label excerpts.
Ativan is made/marketed/manufactured by multiple companies and packaging lists manufacturer/distributed-by/NDC/MA identifiers to confirm the exact company for that version.
No prescribing-information support was provided for these product/distribution/packaging/third-party database statements.
Ativan is marketed/manufactured by generic and brand manufacturers through licensing arrangements.
No prescribing-information support was provided for this manufacturing/licensing claim.
Contradictions
Important Omissions
No contraindications, detailed dosing regimen, monitoring specifics, or administration/storage instructions were addressed in the AI response beyond the boxed-warning-related topics provided; if the original question required those, they would be material omissions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The key safety-related claims evaluated (opioid co-use boxed warning, abuse/misuse/addiction, dependence/withdrawal with taper guidance) are label-supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several non-label administrative/manufacturer/database statements are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Limit claims to prescribing-information content when evaluating FDA labeling; remove or qualify non-label distribution/manufacturer/database statements unless the label excerpts explicitly support them.